https://scholars.lib.ntu.edu.tw/handle/123456789/457865
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | PO-CHIN LIANG | en_US |
dc.contributor.author | YAO-MING WU | en_US |
dc.contributor.author | Huang C.-C. | en_US |
dc.contributor.author | KAI-WEN HUANG | en_US |
dc.contributor.author | CHIA-HSIEN CHENG | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | ZHONG-ZHE LIN | en_US |
dc.creator | Shao Y.-Y.;Liang P.-C.;Yao-Ming Wu;Huang C.-C.;Huang K.-W.;Cheng J.C.;Hsu C.-H.;Hsu C.;Cheng A.-L.;Lin Z.-Z. | - |
dc.date.accessioned | 2020-02-11T07:58:41Z | - |
dc.date.available | 2020-02-11T07:58:41Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883817277&doi=10.1111%2fliv.12207&partnerID=40&md5=b63d8385e4239374d976aaabe8846b11 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/457865 | - |
dc.description.abstract | Background & Aims: For patients with advanced hepatocellular carcinoma (HCC) who have failed first-line anti-angiogenic therapy, there is no salvage treatment. Hepatic arterial infusion of chemotherapy (HAIC) has been reported to achieve substantial treatment responses in HCC patients. We aimed to explore the feasibility of using HAIC as second-line therapy for advanced HCC. Methods: We retrospectively reviewed all consecutive patients who received HAIC for advanced HCC after failure of first-line anti-angiogenic therapy at a single institute. Patients received HAIC with 60 mg/m2 cisplatin on Day 2, and 500 mg/m2/d dose of 5-fluorouracil on Days 1-3. The treatment was repeated every 21 days and continued until disease progression or the occurrence of intolerable toxicities. Tumour assessment was performed after every 3 cycles of HAIC following RECIST criteria, version 1.0. Results: A total of 23 patients were included. Eleven (48%) patients had main portal vein thrombosis. Liver reserve was classified as Child-Pugh A in 19 (83%) patients and B in 4 (17%) patients. No complete response was observed, although 6 (26%) patients showed partial responses. The median progression-free survival was 4.4 months, and the median overall survival was 7.5 months. Common toxicities included bone marrow suppression, elevated transaminase levels, neutropenia, nausea and malaise. Only 7 (30%) patients experienced grade 3 or 4 toxicities, and no patients withdrew from the therapy because of intolerable or life-threatening toxicities. Conclusion: HAIC is a feasible second-line therapy for patients with advanced HCC who have failed anti-angiogenic therapy. ? 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | - |
dc.relation.ispartof | Liver International | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; angiogenesis inhibitor; antibiotic agent; bevacizumab; bilirubin; brivanib; cisplatin; creatinine; doxorubicin; erlotinib; fluorouracil; heparin; nintedanib; oxaliplatin; sorafenib; UFT; urokinase; adult; advanced cancer; aged; alanine aminotransferase blood level; anemia; antiangiogenic therapy; article; bacteremia; bilirubin blood level; bone marrow; cancer chemotherapy; cancer growth; cancer patient; catheter occlusion; cellulitis; Child Pugh score; clinical article; creatinine blood level; drug efficacy; drug treatment failure; female; hepatic artery; hepatitis B; hepatitis C; human; hypertransaminasemia; leukocyte count; leukopenia; liver cell carcinoma; male; neutropenia; pilot study; portal vein thrombosis; progression free survival; retrospective study; stomach varices; thrombocyte count; thrombocytopenia; Anti-angiogenic therapy; hepatic arterial infusion of chemotherapy; hepatocellular carcinoma; salvage therapy; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Pilot Projects; Retrospective Studies; Survival Analysis; Taiwan; Tomography, X-Ray Computed | - |
dc.title | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/liv.12207 | - |
dc.identifier.pmid | 23714197 | - |
dc.identifier.scopus | 2-s2.0-84883817277 | - |
dc.relation.pages | 1413-1419 | - |
dc.relation.journalvolume | 33 | - |
dc.relation.journalissue | 9 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.dept | Medical Imaging-NTUHHC | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Surgery-NTUCC | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Medical Service-NTUCC | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Center for Quality Management and Infection Control-NTUCC | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-6674-2926 | - |
crisitem.author.orcid | 0000-0002-1720-7863 | - |
crisitem.author.orcid | 0000-0001-6375-8714 | - |
crisitem.author.orcid | 0000-0002-2007-0220 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | NTU Hsin-Chu Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。